UNSPSC 51373403: Acetaminophen/chlorpheniramine/codeine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373403 Acetaminophen/chlorpheniramine/codeine/phenylephrine is a Commodity code covering branded and generic multi-source pharmaceuticals and over-the-counter products procured by state and local health departments, emergency services, and cooperative purchasing alliances for community health initiatives and institutional use. State and local governments buy these products through competitive solicitation to stock health facilities, emergency response programs, and community health centers, with quantities ranging from hundreds to thousands of units annually depending on the issuing jurisdiction's scope and patient population.

Issuing bodies span county health departments, state procurement offices administering cooperative purchasing vehicles, and multistate alliances. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement represent recent active buyers. The geographic spread includes Florida and Minnesota, with MMCAP's cooperative extending to participating jurisdictions including Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026. MMCAP's evaluation weights pricing competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent on administrative fee compliance, 5 percent on EDI capability, and 5 percent on agreement to a 3 percent administrative fee. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence.